Incretin Atlas › Molecules › CT-388
CT-388
GIP/GLP-1 · s.c. · Roche
Summary
- Also known as
- Roche / Carmot
- Mechanism
- GIP/GLP-1
- Route
- s.c.
- Company
- Roche
- Highest development stage
- phase 3
- Status (as of data cut)
- Phase 3 (Enith1, Enith2 and a third trial) recruiting since Mar 2026; phase 2 (48 weeks) presented at EASD 2026 verify
- Next milestone
- Phase 3 results (primary completion 2028)
Sources for the status
- Hoffmann-La Roche. A Phase III, Randomized, Double-Blind, Placebo-Controlled, Parallel Group Study to Evaluate the Efficacy and Safety of Once-Weekly RO7795068 Administered to Participants With Obesity or Overweight Without Type 2 Diabetes (Enith1). ClinicalTrials.gov identifier NCT07351045. Bethesda (MD): National Library of Medicine. Available from: https://clinicaltrials.gov/study/NCT07351045
- Hoffmann-La Roche. A Phase III, Randomized, Double-Blind, Placebo-Controlled, Parallel Group Study to Evaluate the Efficacy and Safety of Once-Weekly RO7795068 Administered to Participants With Obesity or Overweight and Type 2 Diabetes (Enith2). ClinicalTrials.gov identifier NCT07351058. Bethesda (MD): National Library of Medicine. Available from: https://clinicaltrials.gov/study/NCT07351058
Trial arms: weight, HbA1c and tolerability
| Trial | Arm | Population | Weeks | n | Weight, efficacy | Weight, treatment-policy | HbA1c, pp | AE discontinuation, % | Any discontinuation, % | Nausea, % | Vomiting, % | SAE, % | SBP, mmHg | Status |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| CT-388 phase 2 | CT-388 24 mg | obesity | 48 | — | −22.7 % vs −0.2 % Δ −22.5 pp | — | — | — | — | — | — | — | — | verified |
| CT-388-104 (T2D) | enicepatide 24 mg | t2d | 48 | — | — | —−15.5 % estimand not specified | −2.6 | — | — | — | — | — | — | press release |
Weight: percent change from baseline, drug vs placebo or comparator, Δ = difference in percentage points. Efficacy estimand = effect while on treatment (hypothetical strategy); treatment-policy = all randomised participants regardless of adherence (ITT). AE discontinuation = stopped study drug for any adverse event. Hover a status for its definition.
Notes
- CT-388 24 mg: Abstract reports up to −22.7 % (absolute) and −22.5 % placebo-adjusted at 24 mg, 48 weeks; placebo derived as −0.2 %
- enicepatide 24 mg: Topline release: placebo results not disclosed; estimand not stated.
Verbatim quotes from the source (2)
- CT-388 24 mg · weight_eff · Conclusion
CT-388 demonstrated significant, dose-dependent WL of up to 22.7%
- enicepatide 24 mg · weight_unsp · company announcement
The mean weight loss at 48 weeks in the 24 mg enicepatide arm was 15.5
Registered trials (5)
From ClinicalTrials.gov and the atlas registry sweep; phase 3 and outcome trials first.
| Trial | Indication | Phase | Status | Start → primary completion | n | Result | Registry |
|---|---|---|---|---|---|---|---|
| Enith-MACE A Clinical Study Testing Enicepatide in Participants Living With Overweight or Obesity and Cardiovascular Disease | CV outcomes | Phase 3 | not yet recruiting | 2027-01 → 2031-03 | 8200 | not yet recruiting | NCT07918846 |
| ENI-SPIRE-2 A Clinical Study to Evaluate the Effects of Enicepatide Versus Tirzepatide in Participants With Type 2 Diabetes and Inadequate Blood Sugar Control on Oral Glucose-Lowering Medications | T2D | Phase 3 | not yet recruiting | 2026-12 → 2029-04 | 948 | not yet recruiting | NCT07889648 |
| NCT07670416 · China A Study to Evaluate the Effects of Enicepatide in Participants With Obesity or Overweight, With or Without Type 2 Diabetes | Obesity | Phase 3 | recruiting | 2026-07 → 2028-02 | 300 | recruiting | NCT07670416 |
| Enith1 A Clinical Study to Evaluate the Effects of Enicepatide (RO7795068) in Participants With Obesity or Overweight Without Type 2 Diabetes | Obesity | Phase 3 | recruiting | 2026-03 → 2028-07 | 2000 | recruiting | NCT07351045 |
| Enith2 A Clinical Study to Evaluate the Effects of Enicepatide (RO7795068) in Participants With Obesity or Overweight and Type 2 Diabetes | Obesity | Phase 3 | recruiting | 2026-03 → 2028-08 | 1600 | recruiting | NCT07351058 |
Primary sources
- Ildiko Lingvay et al. Ct-388, a camp signal-biased GLP-1/GIP receptor agonist, achieves clinically meaningful weight loss in people with overweight/obesity: results from the 48-weeks phase 2 study. Abstract 125. EASD 2026 Annual Meeting; 2026 Sep 29–Oct 3; Milan. [Session: OP 21 Incretin therapies: from mechanism to the real world]
- Roche. Enicepatide phase II results in type 2 diabetes with overweight or obesity [ad hoc announcement]. 2026 Sep 22. Available from: https://www.roche.com/media/releases/med-cor-2026-09-22
How to cite this page
Medical Adviser's Group. Incretin Atlas: CT-388. Data cut 12 November 2026. https://docs.mdwrt.app/infographics/incretin-atlas/ct-388/ Data: doi:10.5281/zenodo.23473913. Accessed 16 November 2026.
Cite the primary publication for any single result; every value above links to it.